Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Add-on to Ipragliflozin in T2DM
NCT02577016Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Nov 2015; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02577016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577016.